Protagonist Therapeutics Reports Granting of Inducement Awards [Yahoo! Finance]
Protagonist Therapeutics (PTGX) was given a new $121.00 price target by Truist Financial Corporation.
Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge [Yahoo! Finance]
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Do Protagonist Therapeutics' (PTGX) Derisked Drugs Have Blockbuster Potential? [Yahoo! Finance]